Loading...
Loading...
TGTX| Name | Value |
|---|---|
| Revenues | 165.8M |
| Cost of Revenue | 3.5M |
| Gross Profit | 162.3M |
| Operating Expense | 47.5M |
| Operating I/L | 114.8M |
| Other Income/Expense | -0.9M |
| Interest Income | 3.7M |
| Pretax | 113.9M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | 113.9M |
TG Therapeutics, Inc. is a biopharmaceutical company specializing in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's product candidates include Ublituximab, an investigational monoclonal antibody for B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis; Umbralisib, an oral inhibitor for CLL and lymphoma; Cosibelimab, a human monoclonal antibody for PD-L1; TG-1701, an orally available BTK inhibitor; and TG-1801, a bispecific CD47 and CD19 antibody. Additionally, the company has licensed preclinical programs and collaboration agreements with several pharmaceutical companies.
